You are here

Article Text

Article menu

Download PDFPDF

Review
Plasma exchange in neurological disease
  1. Chinar Osman1,
  2. Rachel Jennings1,
  3. Khaled El-Ghariani2,
  4. Ashwin Pinto1
  1. 1 Neurosciences, Wessex Neurological Centre, Southampton, UK
  2. 2 Therapeutics and Tissue Services, NHS Blood and Transplant, Sheffield Teaching Hospitals NHS Trust and the University of Sheffield, Sheffield, UK
  1. Correspondence to Dr Chinar Osman, Neurosciences, Wessex Neurological Centre, Southampton SO16 6YD, UK; chinar.osman{at}uhs.nhs.uk

Abstract

Plasma exchange is a highly efficient technique to remove circulating autoantibodies and other humoral factors rapidly from the vascular compartment. It was the first effective acute treatment for peripheral disorders such as Guillain-Barré syndrome and myasthenia gravis before intravenous immunoglobulin became available. The recent recognition of rapidly progressive severe antibody-mediated central nervous system disorders, such as neuromyelitis optica spectrum disorders and anti-N-methyl-D-aspartate-receptor encephalitis, has renewed interest in using plasma exchange for their acute treatment also. In this review we explain the principles and technical aspects of plasma exchange, review its current indications, and discuss the implications for its provision in the UK.

  • neuroimmunology
  • evidence-based neurology
  • clinical neurology

http://dx.doi.org/10.1136/practneurol-2019-002336

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Introduction

    Plasma exchange was first described in 1914.1 Blood components are removed from the body and separated, allowing the plasma component alone to be extracted. The plasma is replaced with an appropriate fluid, commonly human albumin solution. Plasma exchange is effective at removing immunoglobulins and other humoral components from the plasma fraction.

    Several neurological disorders are mediated by pathological antibodies against cell surface antigens, including neuromuscular disorders, such as myasthenia gravis, and central nervous system (CNS) disorders, such as anti-N-methyl-D-aspartate (NMDA) receptor encephalitis. The mechanism of action of plasma exchange appears more complex than simply removing circulating pathogenic antibody from the circulation. It probably has additional immunomodulatory effects including removal of immune complexes and cytokines as well as changing the numbers of immune cells and the function of regulatory T cells (Treg) and natural killer cells.2

    The technique was first introduced as a possible treatment for Guillain-Barré syndrome in 19783 and randomised trials published between 1985 and 1987 showed its significant benefit.4 5 In 1976 Newsom-Davis and colleagues6 showed plasma exchange was also an effective treatment for myasthenia gravis, confirmed by subsequent cases.7 8

    By the end of the 1980s, plasma exchange was widely used in regional neurological centres and intensive care units as first-line treatment for acute Guillain-Barré syndrome and myasthenic crisis. However, the training required for staff to operate the complex machinery, and the need for central venous access prevented its more widespread use smaller hospitals.

    Intravenous immunoglobulin is also a well-established treatment for a range of antibody-mediated autoimmune disorders. It was first reported to be effective in treating children with immune thrombocytopenic purpura in 1981,9 and was subsequently found to be as effective as plasma exchange in treating myasthenia gravis10–12 and Guillain-Barré syndrome.13 14

    Intravenous immunoglobulin has complex mechanisms of action. As with plasma exchange, it accelerates removal of pathogenic autoantibodies from the circulation by saturating the neonatal Fc receptor, thereby preventing recycling of endogenous immunoglobulin. Intravenous immunoglobulin has many practical advantages over plasma exchange, particularly because it does not require highly specialist staff training or insertion of a central venous catheter. It can therefore be given in local hospitals, without needing to transfer patients to neurological centres. Also, critically unwell patients can receive intravenous immunoglobulin, with less risk than with plasma exchange of haemodynamic instability and immune compromise from removal of immunoglobulin. The use of intravenous immunoglobulin in the 1990s as an effective treatment for Guillain-Barré syndrome and myasthenia gravis led to significantly fewer neurological patients needing plasma exchange, and subsequent loss of skill and expertise in neurological units to deliver this treatment.15

    Recently, several antibody-mediated CNS disorders have been identified, including neuromyelitis optica spectrum disorders (NMOSD), acute disseminated encephalomyelitis (ADEM)16–19 and autoimmune encephalitis.20 Collectively, these newly recognised CNS autoimmune disorders pose significant clinical challenges to neurologists due to their rapid progression and the risk of permanent neurological disability if not treated early and aggressively. Although there is little evidence from randomised clinical trials, experience from published case series suggests that early multimodal immunotherapy is important to improve prognosis. Typical acute treatment regimens include plasma exchange or intravenous immunoglobulins—to reduce circulating autoantibodies quickly—together with intravenous corticosteroids. National Health Service (NHS) England has now also approved rituximab as a second-line treatment for neuromyelitis optica and anti-NMDA receptor (NMDAR) encephalitis.21

    It is timely to review the role of plasma exchange in neurological disorders given important recent developments. First, its technology has advanced significantly in the last 20 years, now allowing treatment via peripheral venous access in local hospitals as well as regional centres. Second, the rapid global increase in intravenous immunoglobulin use has significantly increased costs and constrained the UK supply, with around 15% less intravenous immunoglobulin available than required for current demand. Third, the recent recognition of devastating rapidly progressive antibody-mediated CNS diseases, such as NMOSD and autoimmune encephalitis secondary to antibodies to LGI1/CASPR2 and NMDA, has led to renewed interest in plasma exchange as an effective treatment to reduce the concentration of circulating autoantibodies rapidly.

    In this article, we review the recent advances in plasma exchange technology, and the evidence for using it to treat neurological disorders with reference to the recently published guidelines from the American Association of Neurologists (AAN) and the American Society for Apheresis (ASFA). We provide practical information to guide neurologists in the choice of plasma exchange variables, such as the volume of plasma to be exchanged and the frequency and total number of exchanges. Finally, we review current provision of plasma exchange in the UK and highlight how we might improve access to these services for neuroimmunology patients.

    Technical considerations

    Apheresis equipment separates blood components using centrifugation or filtration; either can be used for plasma exchange. Filtration technology separates blood components based on their particle size. Plasma is the easiest to filter, then platelets, red cells, lymphocytes and lastly granulocytes in this order. Filtration occurs across a flat-plate membrane or more commonly in a hollow-fibre system in which blood is pumped into a bundle of hollow fibres with side pores contained within a cylinder. During the exchange, the patient’s plasma leaves the fibres through the side pores, then diverted and replaced by an appropriate replacement fluid. Such a system requires maintaining an appropriate transmembrane pressure to ensure smooth flow of plasma without plugging the pores with cellular components. Centrifugation technology separates blood components on the basis of their specific gravity. Whole blood is pumped into a separation chamber, for example, a rotating bowel or a belt-shaped channel, where the dense red cells are pushed to the periphery, followed by white cells, platelets and then plasma. The machine applies an appropriate g force and uses sensors to detect a state of equilibrium during which the desirable separation of components has been reached with identifiable interface between components. During the exchange, the patient’s plasma is diverted into a collection bag and replaced with a replacement fluid while other components are returned to the patient.22

    Although earlier comparison found both techniques had similar safety and efficiency, they are not used equally across medical specialities, with centrifugal machines more commonly used in apheresis services in the UK and North America. Filtration, being conceptually related to dialysis, is mainly used in renal units. Filtration machines are smaller and use lower extra-corporeal volume making them easier to use for smaller patients; they are also more efficient in removing cellular debris. The technique is quicker and can exchange more plasma volume in shorter periods of time than centrifugal machines. However, filtration uses heparin to anticoagulate the extra corporeal circuit. This also anticoagulates the patient’s blood and may increase the risk of bleeding in patients with thrombocytopenia or a recent biopsy. The blood–filter interactions previously caused allergic reactions, but newer technologies have improved on this. However, such an interaction may activate the kallikrein–kinin system, creating high serum concentration of bradykinin that can cause an anaphylactoid response in patients using angiotensin-converting-enzyme inhibitors. Plasma exchange via membrane filtration invariably requires placement of a central venous catheter for the procedure.

    Centrifugal equipment uses citrate to anticoagulate the extracorporeal circuit, with no anticoagulant effects for patients. More importantly, centrifugal machines are more versatile and haematology departments commonly use them to separate, collect and manage cellular components from the patient, allowing efficient stem cell collection, red cell exchange and so on.22 Existing filtration techniques do not commonly separate different cell types. Moreover, there are theoretical concerns that filtration may retain some pathological large proteins that cannot be removed because of their size or electrical charges. Although there are no trial data to support these concerns, haematologists only use centrifugal techniques to treat thrombotic thrombocytopenic purpura. Centrifugal machines are slower because of the limitation in the volume of citrate that can be safely returned to patients without causing significant hypocalcaemia and because of the time required to establish adequate interface between different components of blood. Importantly, plasma exchange via the centrifugal system can be delivered through peripheral venous access as well as central venous access. Typically, plasma exchange procedure via centrifugation can be completed in adults in about 90 min (table 1).

    View this table:
    Table 1

    Comparison of plasma exchange techniques

    For safe and effective plasma exchange, the neurologist must decide on three important factors.

    The first decision is the plasma volume to be exchanged. This is typically one plasma volume but higher volumes of 1.3–1.5 can be used if necessary, for example, in patients with catastrophic presentation of NMOSD who need a higher clearance of circulating component.23

    The second decision is the frequency of procedures. In our unit, we perform alternate day exchanges. However, most units perform daily exchanges over 5 days. It may be appropriate to perform daily exchanges, at least for the first three exchanges, followed by alternate days with the assumption that this will allow more pathological molecules including autoantibodies to return from the extravascular space to the circulation and hence be removed.

    The third decision is the number of exchanges to complete a full cycle. Patients receiving plasma exchange for maintenance therapy may require fewer exchanges. In our own unit, we perform three exchanges of one plasma volume on alternate days every 6 weeks in patients with myasthenia gravis and stiff-person syndrome, with good outcomes.

    Plasma exchange is relatively safe, with most significant side effects originating from the method of vascular access. Central venous access carries a significantly higher risk of complications than peripheral access, as noted in a retrospective study of plasma exchange in myasthenia gravis.24 The anticoagulant used in extra-corporal circulation, mostly citrate, can cause toxicity in the form of sensory symptoms and occasionally cardiac arrhythmia. Reactions to the replacement fluids are very rare with human albumin solution. Plasma exchange must be completed with trained staff using validated and maintained equipment.25

    Role of plasma exchange in antibody-mediated and metabolic neurological conditions

    Peripheral nervous system disorders

    Guillain-Barré syndrome

    There is convincing evidence that Guillain-Barré syndrome is caused by antibodies to gangliosides and other neural antigens with complement fixation leading to peripheral nerve damage.26 Several validated large randomised-controlled trials have shown significant clinical improvement in those receiving plasma exchange.4 5 13 14

    A recent Cochrane review in 2017 of adults with Guillain-Barré syndrome found moderate-quality evidence showing significantly more improvement with plasma exchange than with supportive care alone, without a significant increase in serious adverse events.27 The AAN28 and ASFA29 guidelines support using plasma exchange in Guillain–Barré syndrome as an established and effective treatment with a strong level of evidence.

    Chronic inflammatory demyelinating polyneuropathy

    Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic autoimmune demyelinating disease of the peripheral nervous system presenting with progressive relapsing weakness and sensory loss in limbs.30 The clinical effectiveness of plasma exchange in CIDP was demonstrated in a randomised double-blind placebo controlled trial that showed improvement in neurological disability score versus the placebo arm.31 A further randomised double-blind placebo controlled study confirmed the previous study findings of clinical benefit but noted a waning of clinical effect after 2 weeks.32

    A Cochrane review concluded that there is moderate-to-high quality evidence from two small trials showing that plasma exchange gave short-term improvement in disability and nerve function. However, plasma exchange may be followed by rapid deterioration, with two-thirds of participants suffering a relapse requiring maintenance plasma exchange.33

    The AAN28 and ASFA29 conclude that plasma exchange is effective in CIDP and can be offered as a first line agent, where indicated, with strong level of evidence.

    Myasthenia gravis

    Myasthenia gravis is an autoimmune disorder in which antibodies against either the skeletal muscle nicotinic acetylcholine receptor or other antigens at the neuromuscular junction (eg, muscle-specific kinase) impair neuromuscular transmission, causing fatigable weakness. Between 1977 and 2000, there were multiple case reports and series from a total 379 patients with myasthenia gravis reporting benefit from plasma exchange.34 35

    Although plasma exchange and intravenous immunoglobulin have been found to be equally effective in myasthenia gravis,11 in our experience the clinical response to plasma exchange is often more rapid than with intravenous immunoglobulin.

    Further case reports and series have shown excellent response to plasma exchange with improvement in respiratory failure.7 8 36 A retrospective class II study compared 19 patients treated with single session of plasma exchange before thymectomy versus 32 treated with thymectomy alone. Patients treated with plasma exchange had fewer crises in the following month and year with a greater postoperative remission at 5–7 years.37

    We need further research comparing plasma exchange with alternative short-term treatments for myasthenic crisis and to determine the value of long-term plasma exchange for treating myasthenia gravis.38

    The AAN28 and ASFA29 conclude that in the last few year randomised studies have proven the clinical effectiveness of plasma exchange in moderate-to-severe myasthenia gravis and for prethymectomy patients.

    Paraproteinemic polyneuropathies

    Paraproteinemic polyneuropathies are progressive neuropathies involving the peripheral nerves in association with a monoclonal gammopathy of IgA. IgG or IgM. About half of IgM paraproteins associated with peripheral polyneuropathy have specificity for myelin-associated glycoprotein.39 A double-blind trial of 39 patients with neuropathies associated with IgG, IgA or IgM monoclonal gammopathies of unknown significance (MGUS) randomised patients into placebo plasma exchange or true plasma exchange two times per week for 3 weeks. The IgG and IgA MGUS-associated polyneuropathy group obtained clinical benefit from plasma exchange but not the patients with IgM paraprotein.40

    The AAN28 and ASFA29 guidelines conclude that plasma exchange can be considered in polyneuropathy associated with IgA or IgG MGUS, but not IgM, with strong level of evidence.

    Stiff-person syndrome

    Stiff-person syndrome is a rare chronic disorder characterised with fluctuating muscle rigidity in trunk and limbs and hypersensitivity to noise/touch and emotional distress resulting in muscle spasms. Up to 90% of patients have serum GAD-65 antibodies.41 A systematic literature review identified a total of 26 patients diagnosed with anti-GAD65 positive stiff-person syndrome and found that 42% of patients showed significant symptomatic improvement after plasma exchange.42

    A retrospective analysis of 10 patients with anti-GAD65 positive stiff-person syndrome found that plasma exchange may help these patients, both for acute exacerbations and long-term maintenance.43

    The ASFA29 conclude that plasma exchange may be effective in patients with stiff-person syndrome who have not responded to first-line therapy, but with only low-quality evidence available.

    Refsum’s disease

    Refsum’s disease is an autosomal recessive disorder of phytanic acid metabolism. Patients present with retinitis pigmentosa, peripheral neuropathy, cerebellar ataxia, sensorineural deafness and anosmia.44 Acute clinical deterioration in Refsum’s disease is associated with high plasma phytanic acid concentrations and can be treated with plasma exchange. Several published small case series of patients with Refsum’s disease have shown significant and rapid clinical improvement in patients in whom plasma exchange has lowered the plasma phytanic acid concentration.45–47

    Plasma exchange is indicated in Refsum’s disease when there is worsening clinical condition or failure of dietary control to reduce the high plasma phytanic acid levels. The ASFA29 concluded that it is possibly effective based on the individual case series and reports.

    CNS disorders

    Acute disseminated encephalomyelitis

    ADEM is a CNS acute inflammatory demyelinating disease that often has a monophasic course but can relapse and can be difficult to distinguish from multiple sclerosis. Recent evidence suggests that up to half of patients with ADEM have serum antibodies to myelin-oligodendrocyte glycoprotein (MOG), suggesting the disorder may be antibody-mediated in many people. Patients can present with altered mental status, encephalopathy, ataxia, hemiparesis, and may progress to coma.48 Most are initially treated with intravenous corticosteroids.49

    In a small case series, four out of 10 ADEM patients who had not responded to corticosteroids significantly improved with plasma exchange.50 Many of the reported case series include patients with several different demyelinating syndromes (eg, acute transverse myelitis, ADEM and multiple sclerosis), making it difficult to evaluate how effective plasma exchange is in specific CNS demyelinating diseases.51–53

    The AAN and ASFA conclude that plasma exchange may be effective treating ADEM particularly in those unresponsive to corticosteroids.29

    Neuromyelitis optica spectrum disorders

    NMOSD comprise a group of inflammatory disorders characterised by antibody-mediated inflammation involving the optic nerve and spinal cord. A significant proportion of patients have serum antibodies to aquaporin four and MOG.17–19 First line is pulsed intravenous methylprednisolone 1000 mg.54 In severe NMOSD cases, expert neurologists generally recommend starting plasma exchange as well, to remove circulating autoantibody and complement rapidly in the hope that this will improve prognosis.55

    In a retrospective review of 59 consecutive patients with acute severe CNS demyelination who received plasma exchange at the Mayo Clinic between 1984 and 2000, six out of 10 NMOSD patients responded, typically within days.50 The timing of plasma exchange to treat acute severe NMOSD is important. Of 60 patients with acute attacks of NMOSD treated in this way, the probability of complete recovery reduced from 50% if plasma exchange was given at day 0, to 1%–5% if it was delayed to day 20.23 Plasma exchange improves the short-term prognosis of NMOSD relapses if given early and is has proven effectiveness regardless of NMOSD-IgG status.55

    A large retrospective analysis of 185 patients with relapsing NMOSD found that first-line therapy with plasma exchange may be superior to high-dose corticosteroid pulse therapy in achieving complete remission in transverse myelitis but not in optic neuritis. Escalation therapy with plasma exchange increases remission rates and should be offered in appropriate cases.56

    The AAN28 and ASFA29 conclude that plasma exchange is probably effective in corticosteroid-refractory acute attacks but probably ineffective as a maintenance therapy.

    Multiple sclerosis

    Multiple sclerosis is a relapsing progressive demyelinating disorder of the CNS white matter, thought to be an autoimmune disorder with genetic predisposition influenced by environmental factors.57 Previous reviews have concluded that plasma exchange provides no therapeutic benefit in the chronic progressive forms of multiple sclerosis.58 59 However, there is evidence that those presenting with acute attacks, due to a humoral pattern of immunopathological demyelination, may respond best to plasma exchange. All 10 patients with acute CNS relapses associated with pattern II (humoral) demyelination achieved moderate to substantial functional neurological improvement following plasma exchange compared with no patients with pattern I or pattern III demyelination.60 This reported case series from the Mayo Clinic predates the identification of antibodies to MOG in patients with ADEM and NMOSD. It is possible therefore that the group of atypical MS patients with acute fulminating disease that responded to plasma exchange in this case series included patients with antibodies to MOG.

    The AAN28 and AFSA29 conclude that plasma exchange is probably effective as an adjuvant treatment for severe relapsing forms of multiple sclerosis and in corticosteroid-unresponsive fulminant forms with a strong level of evidence; however, it is unlikely to be effective in progressive forms.

    Autoimmune encephalitis

    The autoimmune encephalitides comprise a group of uncommon and frequently devastating neurological disorders that typically present with a combination of seizures, altered mental status, cognitive impairment and memory loss, together with movement disorders. The incidence and prevalence of autoimmune encephalitis is probably equal to that of the infective encephalitides.61

    In recent years, autoantibodies targeting cell surface proteins associated with ligand and voltage-gated ion channels have been identified in a high proportion of patients with autoimmune encephalitis, greatly increasing our understanding of the pathogenesis of these disorders. Two of the the most common autoimmune encephalitis syndromes include encephalitis associated with antibodies to the NMDAR20 and limbic encephalitis due to antibodies that target LGI1 and CASPR2 as part of the voltage-gated potassium channel complex.62

    LGI1 and CASPR2 associated encephalitis

    In a retrospective analysis of patients with LGI1 and CASPR2 autoimmune encephalitis, four out of seven patients treated with plasma exchange in conjunction with corticosteroids and intravenous immunoglobulins had complete resolution of symptoms and two out of seven had mild improvement. Giving corticosteroids early led to a faster decrease in autoantibody titres.63

    In an open-label prospective study of patients with LGI1 and CASPR2 autoimmune encephalitis treated with combination immunotherapy comprising plasma exchange, intravenous immunoglobulin and intravenous methylprednisolone, seizures and hyponatraemia remitted within 1 week and cognitive function improved in all patients within 3 months.64

    The ASFA29 conclude that plasma exchange is probably effective in autoimmune encephalitis from observational studies and case series that have shown that LGI1 and CASPR2 autoantibodies decrease with plasma exchange and this is associated with clinical improvement.

    Anti-NMDAR encephalitis

    Encephalitis associated with antibodies to NMDAR typically presents in children and young adults with a characteristic syndrome of abnormal behaviour, dyskinesias and dystonia, memory deficits, autonomic instability and decreased level of consciousness. There is a female predominance, particularly in young adults under 45 years, with an associated ovarian teratoma in up to half of female adults. Current treatment protocols highlight the importance of surgery for ovarian teratoma together with intensive immunotherapy including intravenous corticosteroids, plasma exchange, intravenous immunoglobulins and, in severe cases, rituximab.20 21

    A recent systematic review of plasma exchange in paediatric anti-NMDAR encephalitis identified 71 papers reporting on a total of 242 patients.65 The median time to first treatment was 21 days. In most patients, plasma exchange was combined with corticosteroids and intravenous immunoglobulins. The data confirmed a trend towards better outcome when plasma exchange was performed early and when given with corticosteroids.

    The ASFA29 conclude that plasma exchange is probably effective when given in combination with either corticosteroids or intravenous immunoglobulins and can be considered as part of the first line therapy.

    Other paraneoplastic neurological syndromes

    The paraneoplastic neurological syndromes comprise a diverse group of neurological disorders associated with onconeural antibodies. It is a rare syndrome occurring in 0.1%–1% of oncology patients. Classical paraneoplastic syndromes include cerebellar degeneration, limbic encephalitis, opsoclonus–myoclonus syndrome, subacute sensory ganglionopathy, Lambert-Eaton myasthenic syndrome and dermatomyositis.66

    Plasma exchange reduces serum concentrations of antibodies and cytokines in paraneoplastic neurological syndromes.67 There are only individual case reports of clinical improvement following plasma exchange in treating cerebellar degeneration related to ovarian carcinoma68 69 and Hodgkin’s disease.70 Plasma exchange also helped in cases of paraneoplastic encephalitis with thymoma,71 opsoclonus–myoclonus72 and in a case of paraneoplastic sensorimotor neuropathy.73

    Note, however, that the antibodies detected in most paraneoplastic CNS conditions target intracellular antigens and are not proven to be pathogenic. Thus, reducing the concentration of circulating autoantibodies, either via plasma exchange or intravenous immunoglobulins, will probably not ordinarily lead to clinical improvement.

    The ASFA29 conclude that plasma exchange is possibly effective in paraneoplastic neurological syndromes based on individual case reports and should only be considered as a third-line agent.

    Other paediatric CNS disorders

    Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection

    Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) typically present with abrupt onset of tic behaviour and obsessive-compulsive behaviour in prepubertal children, triggered by group A β-haemolytic streptococcal infection.74 In a randomised placebo-controlled trial of plasma exchange and intravenous immunoglobulin in 29 children with PANDAS, both treatments produced striking improvements in obsessive-compulsive disorder at 1 month after treatment, with a greater improvement in the plasma exchange group than in the intravenous immunoglobulin group.75 In addition, a recent retrospective series 35 patients with PANDAS also found significant improvement in symptoms of obsessive-compulsive disorder, tics and anxiety following plasma exchange.76

    The ASFA29 conclude that plasma exchange is probably effective based on case series and clinical trials.

    Sydenham’s chorea

    Sydenham’s chorea is a paediatric autoimmune post-infective neuropsychiatric disorder caused by antibodies directed against group A β-haemolytic streptococci that cross-react with neuronal antigens in basal ganglia, thereby altering cell signal transduction.77 In a randomised unblinded, controlled study of 18 children with Sydenham’s chorea receiving plasma exchange, intravenous immunoglobulin or prednisolone, all treatment groups responded with no significant difference between groups.78 In addition, a single patient who had failed to respond to corticosteroids and other therapies showed a positive response to plasma exchange.79

    The ASFA29 conclude that plasma exchange is possibly effective in Sydenham’s chorea based on controlled studies and case reports.

    Provision of plasma exchange in UK neurology centres

    In the last 20 years, widespread prescription of intravenous immunoglobulin to treat antibody-mediated neurological disorders has led to a parallel decline in the use of (and therefore availability of) plasma exchange in centres across the UK. Most neurological centres now rely on its provision by external haematology and renal teams for both elective and emergency patients. Renal units typically perform plasma exchange by membrane filtration via central venous catheters, which is suitable only for inpatients or outpatients who have apheresis lines. In contrast, haematology units invariably perform plasma exchange via centrifugation, which allows for treatment of outpatients via peripheral venous access as well as patients with difficult venous access requiring placement of central venous catheter.

    Recent difficulties in securing adequate supplies of intravenous immunoglobulin to treat an increasing range of antibody-mediated neurological disease make it necessary for neurologists to ensure access for plasma exchange at all neurological centres in the UK. NHS Blood and Transplant (NHSBT) has provided therapeutic plasma exchange to neurology patients in England for over 20 years. Specialist regional clinical teams based at eight sites across England (Liverpool, Manchester, Sheffield, Leeds, Birmingham, Bristol, Oxford and London) are able to provide access to plasma exchange at local neurology centres. NHSBT currently performs over a thousand procedures per year for neurology patients in England.

    Larger neurology centres not co-located with NHSBT may choose to establish their own in-house plasma exchange service given the large savings achieved by reducing delays to treatment and the relatively low cost of the investment required in staff training and equipment. As an example, we have established a peripheral day case patient plasma exchange service in 2017 at the Wessex Neurological Centre in Southampton, UK, funded by cost savings over the previous service after purchasing a new Spectra Optia centrifuge machine for peripheral access plasma exchange (figure 1). A recent audit of our plasma exchange data after the first 18 months has shown significantly reduced delay to treatment with good patient outcomes and excellent safety profile.80

    Figure 1
    Figure 1

    Spectra Optia centrifuge machine (picture from https://abdominalkey.com/plasma-exchange/).

    Conclusion

    Plasma exchange is an effective treatment for a range of antibody-mediated neurological diseases (table 2).81 Its indications have widened from initial use in acute treatment of Guillain-Barré syndrome and myasthenia gravis to the management of devastating autoimmune CNS disorders, such as NMOSD and anti-NMDAR encephalitis, where rapid removal of autoantibodies and humoral factors is essential to improve prognosis. Centrifugal plasma exchange machines now enable patients to be treated via peripheral venous access thereby making this treatment available for day case patients. Given the concerns about availability of supply of intravenous immunoglobulins, it is important for neurologists to refamiliarise themselves with plasma exchange technology and to plan for provision of this essential service at neurological centres across the UK.

    View this table:
    Table 2

    Summary of evidence from ASFA/AAN28 29 using the grading of recommendations assessment (GRADE) system from Guyatt et al 81

    Key points

    • Plasma exchange is a highly efficient technique to remove circulating autoantibodies and other humoral factors rapidly from the vascular compartment.

    • Plasma exchange is an effective treatment for a range of antibody-mediated neurological diseases.

    • Centrifugal plasma exchange allows for day case treatment via peripheral venous access.

    • Given the national UK shortage of intravenous immunoglobulin, neurologists need to re-familiarise themselves with plasma exchange treatment.

    References

    1. ↵
      2. Abel JJ ,
      3. Rowntree LG ,
      4. Turner BB
      . Plasma removal with return of corpuscles (plasmaphaeresis). The Journal of pharmacology and experimental therapeutics Vol. V. No. 6, July, 1914. Transfus Sci 1990;11:166–77.
      OpenUrlPubMed
    2. ↵
      2. Reeves HM ,
      3. Winters JL
      . The mechanisms of action of plasma exchange. Br J Haematol 2014;164:342–51.doi:10.1111/bjh.12629
      OpenUrlCrossRefPubMed
    3. ↵
      2. Brettle RP ,
      3. Gross M ,
      4. Legg NJ , et al
      . Treatment of acute polyneuropathy by plasma exchange. The Lancet 1978;312.doi:10.1016/S0140-6736(78)91837-8
    4. ↵
      1. The Guillain-Barre Syndrome Study Group
      . Plasmapheresis and acute Guillain-Barre syndrome. Neurology 1985;35:1096–104.doi:10.1212/WNL.35.8.1096
      OpenUrlCrossRefPubMed
    5. ↵
      1. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome
      . Plasma exchange in Guillain-Bare syndrome: one year follow-up. Ann Neurol 1987;22:753–61.
      OpenUrlCrossRefPubMedWeb of Science
    6. ↵
      2. Pinching AJ ,
      3. Peters DK ,
      4. Newsom Davis J
      . Remission of myasthenia gravis following plasma-exchange. Lancet 1976;2:1373–6.doi:10.1016/S0140-6736(76)91917-6
      OpenUrlPubMedWeb of Science
    7. ↵
      2. Dau PC
      . Plasmapheresis in myasthenia gravis. Prog Clin Biol Res 1982;88:265–85.
      OpenUrlPubMed
    8. ↵
      2. Kornfeld P ,
      3. Ambinder EP ,
      4. Mittag T , et al
      . Plasmapheresis in refractory generalized myasthenia gravis. Arch Neurol 1981;38:478–81.doi:10.1001/archneur.1981.00510080040003
      OpenUrlCrossRefPubMedWeb of Science
    9. ↵
      2. Imbach P ,
      3. Barandun S ,
      4. Baumgartner C , et al
      . High-Dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta 1981.
    10. ↵
      2. Barth D ,
      3. Nabavi Nouri M ,
      4. Ng E , et al
      . Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011;76:2017–23.doi:10.1212/WNL.0b013e31821e5505
      OpenUrlCrossRef
    11. ↵
      2. Gajdos P ,
      3. Chevret S ,
      4. Clair B , et al
      . Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. myasthenia gravis clinical study Group. Ann Neurol 1997;41:789–96.doi:10.1002/ana.410410615
      OpenUrlCrossRefPubMedWeb of Science
    12. ↵
      2. Rønager J ,
      3. Ravnborg M ,
      4. Hermansen I , et al
      . Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 2001.
    13. ↵
      1. Plasma Exchange / Sandoglobulin Guillain-Barre Syndrome Trial Group
      . Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. plasma Exchange/Sandoglobulin Guillain-Barre syndrome trial group. Lancet 1997.
    14. ↵
      2. van der Meché FG ,
      3. Schmitz PI
      . A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 1992;326:1123–9.doi:10.1056/NEJM199204233261705
      OpenUrlCrossRefPubMedWeb of Science
    15. ↵
      2. Clark WF ,
      3. Rock GA ,
      4. Buskard N , et al
      . Therapeutic plasma exchange: an update from the Canadian apheresis group. Ann Intern Med 1999.
    16. ↵
      2. Kitley J ,
      3. Woodhall M ,
      4. Waters P , et al
      . Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79:1273–7.doi:10.1212/WNL.0b013e31826aac4e
      OpenUrlCrossRefPubMed
    17. ↵
      2. Lennon VA ,
      3. Kryzer TJ ,
      4. Pittock SJ , et al
      . Igg marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473–7.doi:10.1084/jem.20050304
      OpenUrlAbstract/FREE Full Text
    18. ↵
      2. Jurynczyk M ,
      3. Messina S ,
      4. Woodhall MR , et al
      . Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 2017;140:3128–38.doi:10.1093/brain/awx276
      OpenUrl
    19. ↵
      2. Cobo-Calvo A ,
      3. Ruiz A ,
      4. Maillart E , et al
      . Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology 2018;90:e1858–69.doi:10.1212/WNL.0000000000005560
      OpenUrl
    20. ↵
      2. Dalmau J ,
      3. Tüzün E ,
      4. Wu H-yan , et al
      . Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25–36.doi:10.1002/ana.21050
      OpenUrlCrossRefPubMedWeb of Science
    21. ↵
      2. Dalmau J ,
      3. Lancaster E ,
      4. Martinez-Hernandez E , et al
      . Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63–74.doi:10.1016/S1474-4422(10)70253-2
      OpenUrlCrossRefPubMedWeb of Science
    22. ↵
      2. Linz C
      . Crookston and Vrielink. In: Principles of Apheresis Technology. 5th edn, 2014.
    23. ↵
      2. Bonnan M ,
      3. Valentino R ,
      4. Debeugny S , et al
      . Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2018.
    24. ↵
      2. Ebadi H ,
      3. Barth D ,
      4. Bril V
      . Safety of plasma exchange therapy in patients with myasthenia gravis. Muscle and Nerve 2013.
    25. ↵
      2. Howell C ,
      3. Douglas K ,
      4. Cho G , et al
      . Guideline on the clinical use of apheresis procedures for the treatment of patients and collection of cellular therapy products. British Committee for standards in haematology. Transfus Med 2015;25:57–78.doi:10.1111/tme.12205
      OpenUrl
    26. ↵
      2. van Doorn PA ,
      3. Ruts L ,
      4. Jacobs BC
      . Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008.
    27. ↵
      2. Chevret S ,
      3. Hughes RAC ,
      4. Annane D , et al
      . Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2017;37.doi:10.1002/14651858.CD001798.pub3
    28. ↵
      2. Cortese I ,
      3. Chaudhry V ,
      4. So YT , et al
      . Evidence-Based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;76:294–300.doi:10.1212/WNL.0b013e318207b1f6
      OpenUrlCrossRefPubMed
    29. ↵
      2. Schwartz J ,
      3. Padmanabhan A ,
      4. Aqui N , et al
      . Guidelines on the use of therapeutic apheresis in clinical Practice—Evidence-Based approach from the writing Committee of the American Society for apheresis: the seventh special issue. J Clin Apher 2016.
    30. ↵
      2. Vallat JM ,
      3. Sommer C ,
      4. Magy L
      . Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010.
    31. ↵
      2. Dyck PJ ,
      3. Daube J ,
      4. O'Brien P ,
      5. O’Brien P , et al
      . Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314:461–5.doi:10.1056/NEJM198602203140801
      OpenUrlCrossRefPubMedWeb of Science
    32. ↵
      2. Hahn AF ,
      3. Bolton CF ,
      4. Pillay N , et al
      . Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain 1996;119:1055–66.doi:10.1093/brain/119.4.1055
      OpenUrlCrossRefPubMed
    33. ↵
      2. Mehndiratta MM ,
      3. Hughes RAC ,
      4. Pritchard J , et al
      . Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2015;314.doi:10.1002/14651858.CD003906.pub4
    34. ↵
      2. Weinstein R
      . Therapeutic apheresis in neurological disorders. J Clin Apher 2000;15:74–128.doi:10.1002/(SICI)1098-1101(2000)15:1/2<74::AID-JCA6>3.0.CO;2-O
      OpenUrlCrossRefPubMedWeb of Science
    35. ↵
      2. Qureshi AI ,
      3. Suri MFK
      . Plasma exchange for treatment of myasthenia gravis: pathophysiologic basis and clinical experience. Ther Apher 2000.
    36. ↵
      2. Goti P ,
      3. Spinelli A ,
      4. Marconi G , et al
      . Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis. Thorax 1995;50:1080–6.doi:10.1136/thx.50.10.1080
      OpenUrlAbstract/FREE Full Text
    37. ↵
      2. Nagayasu T ,
      3. Yamayoshi T ,
      4. Matsumoto K , et al
      . Beneficial effects of plasmapheresis before thymectomy on the outcome in myasthenia gravis. Japanese J Thorac Cardiovasc Surg 2005.
    38. ↵
      2. Gajdos P ,
      3. Chevret S ,
      4. Toyka KV , et al
      . Plasma exchange for generalised myasthenia gravis. Cochrane Database Syst Rev 2002;12.doi:10.1002/14651858.CD002275
    39. ↵
      2. Rison RA ,
      3. Beydoun SR
      . Paraproteinemic neuropathy: a practical review. BMC Neurol 2016;16.doi:10.1186/s12883-016-0532-4
    40. ↵
      2. Dyck PJ ,
      3. Low PA ,
      4. Windebank AJ , et al
      . Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991.
    41. ↵
      2. Ciccotto G ,
      3. Blaya M ,
      4. Kelley RE
      . Stiff person syndrome. Neurol Clin 2013;31:319–28.doi:10.1016/j.ncl.2012.09.005
      OpenUrlPubMed
    42. ↵
      2. Pagano MB ,
      3. Murinson BB ,
      4. Tobian AAR , et al
      . Efficacy of therapeutic plasma exchange for treatment of stiff-person syndrome. Transfusion 2014;54:1851–6.doi:10.1111/trf.12573
      OpenUrl
    43. ↵
      2. Albahra S ,
      3. Yates SG ,
      4. Joseph D , et al
      . Role of plasma exchange in stiff person syndrome. Transfus Apher Sci 2019.
    44. ↵
      2. Gibberd FB ,
      3. Billimoria JD ,
      4. Goldman JM , et al
      . Heredopathia atactica polyneuritiformis: Refsum’s disease. Acta Neurol Scand 1985.
    45. ↵
      2. Gibberd FB
      . Plasma exchange for Refsum’s disease. Transfus Sci 1993.
    46. ↵
      2. Harari D ,
      3. Gibberd FB ,
      4. Dick JPR , et al
      . Plasma exchange in the treatment of Refsum’s disease (heredopathia atactica polyneuritiformis). J Neurol Neurosurg Psychiatry 1991.
    47. ↵
      2. Zolotov D ,
      3. Wagner S ,
      4. Kalb K , et al
      . Long-term strategies for the treatment of Refsum’s disease using therapeutic apheresis. J Clin Apher 2012.
    48. ↵
      2. Hartung H-P
      . Adem: distinct disease or part of the MS spectrum? Neurology 2001;56:1257–60.doi:10.1212/WNL.56.10.1257
      OpenUrlCrossRef
    49. ↵
      2. Chitnis T ,
      3. Tenembaum S ,
      4. Banwell B , et al
      . International pediatric multiple sclerosis Study Group. Mult Scler 2012;18:116–27.
      OpenUrlCrossRefPubMed
    50. ↵
      2. Keegan M ,
      3. Pineda AA ,
      4. McClelland RL , et al
      . Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58:143–6.doi:10.1212/WNL.58.1.143
      OpenUrlCrossRefPubMed
    51. ↵
      2. Weiner HL ,
      3. Dau PC ,
      4. Khatri BO , et al
      . Double-Blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989;39:1143.doi:10.1212/WNL.39.9.1143
    52. ↵
      2. Bigi S ,
      3. Banwell B ,
      4. Yeh EA
      . Outcomes after early administration of plasma exchange in pediatric central nervous system inflammatory demyelination. J Child Neurol 2015.
    53. ↵
      2. Weinshenker BG ,
      3. O'Brien PC ,
      4. Petterson TM , et al
      . A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878–86.doi:10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q
      OpenUrlCrossRefPubMedWeb of Science
    54. ↵
      2. Argyriou AA ,
      3. Makris N
      . Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 2008.
    55. ↵
      2. Bonnan M ,
      3. Cabre P
      . Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int 2012.
    56. ↵
      2. Kleiter I ,
      3. Gahlen A ,
      4. Borisow N , et al
      . Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 2016.
    57. ↵
      2. Rudick RA ,
      3. Cohen JA ,
      4. Weinstock-Guttman B , et al
      . Management of multiple sclerosis. N Engl J Med 1997.
    58. ↵
      2. Weinstein R
      . Therapeutic apheresis in neurological disorders: a survey of the evidence in support of current category I and II indications for therapeutic plasma exchange. J Clin Apher 2008.
    59. ↵
      2. Klingel R ,
      3. Heibges A ,
      4. Fassbender C
      . Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies - Perspectives for immunoadsorption. Atheroscler Suppl 2013.
    60. ↵
      2. Keegan M ,
      3. König F ,
      4. McClelland R , et al
      . Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005.
    61. ↵
      2. Dubey D ,
      3. Pittock SJ ,
      4. Kelly CR , et al
      . Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol 2018.
    62. ↵
      2. Buckley C ,
      3. Oger J ,
      4. Clover L , et al
      . Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001.
    63. ↵
      2. Vincent A ,
      3. Buckley C ,
      4. Schott JM , et al
      . Potassium channel antibody‐associated encephalopathy: a potentially immunotherapy‐responsive form of limbic encephalitis. Brain 2004;127:701–12.doi:10.1093/brain/awh077
      OpenUrlCrossRefPubMedWeb of Science
    64. ↵
      2. Wong SH ,
      3. Saunders MD ,
      4. Larner AJ , et al
      . An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis. J Neurol Neurosurg Psychiatry 2010.
    65. ↵
      2. Suppiej A ,
      3. Nosadini M ,
      4. Zuliani L , et al
      . Plasma exchange in pediatric anti-NMDAR encephalitis: a systematic review. Brain Dev 2016.
    66. ↵
      2. Leypoldt F ,
      3. Wandinger K-P
      . Paraneoplastic neurological syndromes. Clin Exp Immunol 2014;175:336–48.doi:10.1111/cei.12185
      OpenUrlPubMed
    67. ↵
      2. Rosenfeld MR ,
      3. Dalmau J
      . Current therapies for neuromuscular manifestations of paraneoplastic syndromes. Curr Neurol Neurosci Rep 2006.
    68. ↵
      2. Cocconi G ,
      3. Ceci G ,
      4. Juvarra G , et al
      . Successful treatment of subacute cerebellar degeneration in ovarian carcinoma with plasmapheresis. A case report. Cancer 1985;56:2318–20.doi:10.1002/1097-0142(19851101)56:9<2318::AID-CNCR2820560930>3.0.CO;2-9
      OpenUrlCrossRefPubMedWeb of Science
    69. ↵
      2. Ben DY ,
      3. Warner E ,
      4. Levitan M , et al
      . Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin: a case report. Cancer 1996.
    70. ↵
      2. Taniguchi Y ,
      3. Tanji C ,
      4. Kawai T , et al
      . A case report of plasmapheresis in paraneoplastic cerebellar ataxia associated with anti-Tr antibody. Ther Apher Dial 2006.
    71. ↵
      2. Rickman OB ,
      3. Parisi JE ,
      4. Yu Z , et al
      . Fulminant autoimmune cortical encephalitis associated with thymoma treated with plasma exchange. Mayo Clin Proc 2000.
    72. ↵
      2. Armstrong MB ,
      3. Robertson PL ,
      4. Delayed CVP
      . Recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis. Pediatr Neurol 2005.
    73. ↵
      2. Weissman DE ,
      3. Gottschall JL
      . Complete remission of paraneoplastic sensorimotor neuropathy: a case associated with small‐cell lung cancer responsive to chemotherapy, plasma exchange, and radiotherapy. J Clin Apher 1989.
    74. ↵
      2. Swedo SE ,
      3. Leonard HL ,
      4. Garvey M , et al
      . Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998.
    75. ↵
      2. Perlmutter SJ ,
      3. Leitman SF ,
      4. Garvey MA , et al
      . Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999.
    76. ↵
      2. Latimer ME ,
      3. L’Etoile N ,
      4. Seidlitz J , et al
      . Therapeutic plasma apheresis as a treatment for 35 severely ill children and adolescents with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. J Child Adolesc Psychopharmacol 2015.
    77. ↵
      2. Cardoso F ,
      3. Seppi K ,
      4. Mair KJ , et al
      . Seminar on choreas. Lancet Neurol 2006.
    78. ↵
      2. Garvey MA ,
      3. Snider LA ,
      4. Leitman SF , et al
      . Treatment of sydenham’s chorea with intravenous immunoglobulin, plasma exchange, or prednisone. J Child Neurol 2005.
    79. ↵
      2. Miranda M ,
      3. Walker RH ,
      4. Saez D , et al
      . Severe Sydenham’s chorea (chorea paralytica) successfully treated with plasmapheresis. J Clin Mov Disord 2015;2.doi:10.1186/s40734-014-0012-1
    80. ↵
      2. Jennings R ,
      3. Osman C ,
      4. Hill K , et al
      . Outpatient plasma exchange: the Wessex experience. J Neurol Neurosurg Psychiatry 2019.
    81. ↵
      2. Guyatt GH ,
      3. Oxman AD ,
      4. Vist GE , et al
      . Grade: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6.doi:10.1136/bmj.39489.470347.AD
      OpenUrlFREE Full Text
    View Abstract

    Footnotes

    • Contributors CO wrote the draft manuscript. RJ and KE-G contributed to the practicalities of PLEX. AAP reviewed the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Commissioned. Externally peer reviewed by Marguerite Hill, Swansea, UK and Aisling Carr, London, UK

    Other content recommended for you